Kalydeco (ivacaftor)
pCPA File Number:
20726
Negotiation Status:
Concluded with an LOI
Indication(s):
Cystic Fibrosis patients (G551D mutation)
Sponsor/Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
CDA-AMC Project Number:
SR0291-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded: